Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax RateWages, Salaries and Other
Others
Ratios

Sunshine Biopharma (SBFM) Research & Development (2016 - 2026)

Sunshine Biopharma filings provide 11 years of Research & Development readings, the most recent being $73501.0 for Q4 2025.

  • On a quarterly basis, Research & Development fell 50.76% to $73501.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $604308.0, a 35.29% decrease, with the full-year FY2025 number at $604308.0, down 35.29% from a year prior.
  • Research & Development hit $73501.0 in Q4 2025 for Sunshine Biopharma, down from $119298.0 in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $816328.0 in Q4 2023 to a low of $41763.0 in Q4 2022.
  • Median Research & Development over the past 5 years was $205754.5 (2025), compared with a mean of $243905.4.
  • Biggest five-year swings in Research & Development: surged 5177.66% in 2021 and later tumbled 81.71% in 2024.
  • Sunshine Biopharma's Research & Development stood at $91198.0 in 2021, then plummeted by 54.21% to $41763.0 in 2022, then surged by 1854.67% to $816328.0 in 2023, then tumbled by 81.71% to $149272.0 in 2024, then crashed by 50.76% to $73501.0 in 2025.
  • The last three reported values for Research & Development were $73501.0 (Q4 2025), $119298.0 (Q3 2025), and $196232.0 (Q2 2025) per Business Quant data.